摘要
随着临床研究证据的积累,多烯磷脂酰胆碱已被我国多部肝病诊疗指南列为抗炎保肝治疗药物。但限于篇幅,上述指南均未就多烯磷脂酰胆碱的具体临床应用展开论述,也未能给出详尽的循证医学证据。为此,本文以多烯磷脂酰胆碱在各种肝病临床应用的结果作为证据,参照肝病诊疗相关的各项指南和共识,结合肝病治疗的发展趋势,讨论并撰写本专家共识,以期为临床医生进一步提供用药依据。
Polyenphosphatidylcholine are recommended to improve liver function in several national guidelines based on the clinical evidence which showed that polyenphosphatidylcholine were effective in patients with multiple liver diseases.Due to the limited description of data on polyenphosphatidylcholine in previous guidelines,the comprehensive review of polyenphosphatidylcholine in patients with liver diseases is needed.The committee of the treatment with polyenphosphatidylcholine in patients with liver diseases published the present consensus to standardize the clinical use of polyenphosphatidylcholine in patients with liver diseases.
作者
无
徐京杭
Committee of the treatment with polyenphosphatidylcholine in patients with liver diseases
出处
《中华实验和临床感染病杂志（电子版）》
CAS
2017年第4期313-319,共7页
Chinese Journal of Experimental and Clinical Infectious Diseases(Electronic Edition)
基金
北京市医院管理局扬帆计划项目(肝炎专业)(No.ZYLX201402)
登峰计划项目(肝炎专业)(No.DFL20151701)
关键词
多烯磷脂酰胆碱
保肝
专家共识
Polyenphosphatidylcholine
Liver protection
Consensus
